Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds
Paul R. Walker^
Division of Hematology/Oncology, Department of Medicine, Brody School of Medicine at East Carolina University, Greenville, NC, USA
Correspondence to: Paul R. Walker, MD, FACP. Division of Hematology/Oncology, Department of Medicine, Brody School of Medicine at East Carolina University, 600 Moye Blvd, Greenville, NC 27834, USA. Email: firstname.lastname@example.org.
Comment on: Shinohara S, Takahashi Y, Masago K, et al. The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review. J Thorac Dis 2023;15:747-58.
Keywords: Circulating tumor DNA (ctDNA); neoadjuvant; immunotherapy; non-small cell lung cancer (NSCLC)
Submitted Apr 27, 2023. Accepted for publication Jun 02, 2023. Published online Jun 15, 2023.
View this article at: https://circulogene.com/wp-content/uploads/2023/06/JTD-23-699-final_1.pdf